Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Status:
Completed
Trial end date:
2019-06-26
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies dabrafenib and trametinib in treating patients with
ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals